<DOC>
	<DOCNO>NCT00075998</DOCNO>
	<brief_summary>- Purpose : A phase 3 , randomize , double-blind , placebo-controlled trial determine efficacy safety 200 Âµg recombinant Interferon gamma-1b administer subcutaneous ( SC ) injection , compare placebo , patient IPF - Enrollment : Approximately 800 patient enrol approximately 80 center North America Europe - Randomization : 2:1 active-to-placebo ratio - Duration : least 2 year active drug placebo ( rescue therapy permit patient meet predefined criterion )</brief_summary>
	<brief_title>The INSPIRE Trial : A Study Interferon Gamma-1b Idiopathic Pulmonary Fibrosis ( IPF )</brief_title>
	<detailed_description>INSPIRE , large comprehensive clinical trial ever conduct IPF , complete enrol patient mild moderate IPF . Eligible patient receive either Interferon gamma-1b placebo minimum 2 year .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-gamma</mesh_term>
	<criteria>Inclusion criterion : Clinical symptom consistent IPF &gt; = 3 month duration Diagnosis IPF within 48 month randomization Age 40 79 , inclusive Highresolution compute tomographic scan ( HRCT ) show definite IPF . For patient surgical lung biopsy show definite probable usual interstitial pneumonia ( UIP ) , HRCT criterion probable IPF sufficient . For patient age &lt; 50 year : open videoassisted thoracoscopic ( VATS ) lung biopsy show definite probable UIP within 48 month randomization . In addition , feature support alternative diagnosis transbronchial biopsy bronchoalveolar lavage ( BAL ) perform . For patient age &lt; 50 year : At least one follow diagnostic finding , well absence feature specimens result procedure support alternative diagnosis , within 48 month randomization : Open VATS lung biopsy show definite probable UIP Transbronchial biopsy show feature support alternative diagnosis BAL showing feature support alternative diagnosis IPF Disease Severity Progression FVC &gt; = 55 % predict value ( post administration bronchodilator ) Hemoglobin ( Hb ) correct carbon monoxide diffuse capacity/carbon monoxide transfer capacity ( DLCO/TLCO ) &gt; = 35 % predict value At least one either FVC Hbcorrected DLCO/TLCO &lt; = 90 % predict value IPF disease progression evidence one follow within past year absence evidence improvement past year : Absolute decrease &gt; = 10 % FVC Absolute decrease &gt; = 15 % DLCO/TLCO Evidence clinically significant worsen chest X ray HRCT Significant worsen dyspnea Distance walk &gt; = 150 meter ( 492 foot ) O2 saturation &gt; = 83 % &lt; = 6 L/min O2 6 Minute Walk Test ( 6MWT ) oxygen titration procedure Exclusion criterion : 1 . Not suitable candidate enrollment unlikely comply requirement study , opinion Principal Investigator ( PI ) 2 . Forced expiratory volume first second ( FEV1 ) /FVC ratio &lt; 0.6 ( administration bronchodilator ) 3 . Residual volume ( RV ) &gt; 140 % predict ( administration bronchodilator ) 4 . History clinically significant environmental exposure know cause pulmonary fibrosis ( include limit drug , asbestos , beryllium , radiation , domestic bird ) 5 . Known explanation interstitial lung disease , include limited radiation , sarcoidosis , hypersensitivity pneumonitis , bronchiolitis obliterans organize pneumonia , cancer 6 . Diagnosis connective tissue disease , include limited scleroderma , systemic lupus erythematosus , rheumatoid arthritis 7 . Clinical evidence active infection , include limited bronchitis , pneumonia , sinusitis , urinary tract infection , cellulitis 8 . On lung transplantation wait list time randomization Medical Exclusions : 9 . Any history malignancy likely result death , significant disability , likely require significant medical surgical intervention within next 3 year . This include minor surgical procedure localize carcinoma ( e.g. , basal cell carcinoma ) 10 . Any condition IPF , opinion PI , likely result death patient within next 3 year 11 . History unstable deteriorating cardiac , vascular , neurologic disease within previous 6 month , include limited following : Myocardial infarction , unstable angina pectoris , coronary artery bypass surgery , coronary angioplasty Congestive heart failure require hospitalization Uncontrolled arrhythmias Thromboembolic event ( e.g. , deep vein thrombosis , pulmonary embolism ) Transient ischemic attack ( TIAs ) cerebral vascular accident 12 . Any condition , , opinion investigator , might significantly exacerbate know side effect , ( e.g. , flulike syndrome ) associate administration IFN g 1b 13 . History follow medical condition : Multiple sclerosis Seizures within past 10 year take anti seizure medication Severe poorly control diabetes 14 . Pregnancy lactation . Females childbearing potential require negative serum pregnancy test treatment must agree practice abstinence prevent pregnancy least barrier method birth control duration study 15 . Inability tolerate nonsteroidal antiinflammatory drug ( NSAIDS ) acetaminophen ( paracetamol ) 16 . History ethanol abuse past 2 year 17 . Known hypersensitivity IFNg closely related interferon component study treatment 18 . Presence human immunodeficiency virus ( HIV ) chronic viral hepatitis Laboratory Exclusions : 19 . Any following liver function test criterion specify limit : Total bilirubin &gt; 1.5 x upper limit normal ( ULN ) ; aspartate alanine aminotransferase ( AST/SGOT ALT/SGPT ) &gt; 2 x ULN ; alkaline phosphatase &gt; 2 x ULN ; albumin &lt; 3.0 mg/dL 20 . Any following hematology test criterion outside specify limit : WBC &lt; 2,500/mm3 , hematocrit &lt; 30 % &gt; 59 % , platelet &lt; 100,000 /mm3 21 . Creatinine &gt; 1.5 x ULN Concomitant Therapy Exclusions : 22 . Prednisone therapy ( prednisone equivalent , dose adjusted potency ) excess 0.125 mg/kg ideal body weight ( IBW ) per day excess 0.25 mg/kg IBW every day . Patients also exclude stable dose corticosteroid therapy least 28 day prior screen . 23 . Prior treatment IFN g 1b 24 . Investigational therapy ( i.e. , agent approve local regulatory agency ) indication within 28 day prior screen 25 . The following therapy exclude within 28 day prior screen : Investigational therapy IPF , include pirfenidone Any cytotoxic/immunosuppressive agent corticosteroid ( include limit azathioprine , cyclophosphamide , methotrexate , cyclosporine ) Any cytokine modulators ( include limit etanercept , infliximab ) Any therapy target treat IPF ( include limit penicillamine , colchicine , bosentan , Nacetylcysteine [ NAC ] )</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Idiopathic</keyword>
	<keyword>Pulmonary</keyword>
	<keyword>Fibrosis</keyword>
	<keyword>IPF</keyword>
	<keyword>Lung</keyword>
	<keyword>Interferon</keyword>
	<keyword>Gamma</keyword>
	<keyword>Actimmune</keyword>
	<keyword>INSPIRE</keyword>
	<keyword>InterMune</keyword>
</DOC>